Clinical Trial Search

Primary: Change From Baseline in the Number of Actinic Keratosis Lesions in the Treatment Field on Day 56 — -1.54; -1.34; -1.94 lesions — p=0.9518

Primary: Radiation Dose to Primary Operator (RaySafe), Cardiac Catheterization — 18; 39 microsievert

Primary: Number of Participants Who Completed a Semi-Structure Interview — 26 Participants

Primary: Safety: Number of Participants With Any Severe Related Treatment-emergent Adverse Events (TEAEs) Per Infusion (Excluding Infections) — 1; 0 Participants

Primary: C-reactive Protein — 160.7; 173.4; 211.4 ng/mL

Primary: Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to…

Primary: Cmax of Oxycodone Oral Solution. — 5.92 mg/kg

Primary: Pain (Aim 1) — 4.9; 5.2; 1.8; 1.5 units on a scale

Primary: Six-minute Walk Performance — 5.86; -3.92; 30.27; -4.62 meters — p=0.1107

Primary: Percentage of Absolute Oral Bioavailability for Quizartinib As Assessed By Pharmacokinetic Parameters for Area Under the Plasma Concentration-Time Curve Following…

Primary: Occurrence of Apnea — 25; 12; 80; 104 Participants — p=0.0104

Primary: Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point — 6; -23; -56; -60 percent change — p=0.0042

Primary: Primary Outcome - Worst NRS With Movement — 5.6; 3.3; 6.1; 6.4 score on a scale

Primary: Number of Participants With Unsolicited Adverse Events — 0; 0; 0; 0 Participants

Primary: Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1) — 21.7; 35.6; 22.1; 35.8 percentage of subjects — p=<0.001